BiotechTube

CT-P13 SC (Infliximab)

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ulcerative Colitis

Conditions

Ulcerative Colitis

Trial Timeline

Sep 1, 2020 → Jul 11, 2023

NCT ID
NCT04205643

About CT-P13 SC (Infliximab)

CT-P13 SC (Infliximab) is a phase 3 stage product being developed by Celltrion for Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04205643. Target conditions include Ulcerative Colitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04205643Phase 3Completed
NCT03945019Phase 3Completed

Competing Products

20 competing products in Ulcerative Colitis

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
77
MirikizumabEli LillyPhase 2
52
Azathioprine + PlaceboCelltrionApproved
85
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
TacrolimusAstellas PharmaPhase 3
77
tacrolimus + PlaceboAstellas PharmaPhase 3
77
Filgotinib MaleateEisaiApproved
85
AJM300 + PlaceboEisaiPhase 3
77
GSK3050002 + PlaceboEisaiPhase 1
33
adalimumab + placeboEisaiPhase 3
77
E6007 + PlaceboEisaiPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 1
33
Arm1 + Arm 2Zydus LifesciencesPhase 2
52
Mirikizumab + MirikizumabEli LillyPhase 3
77
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 2
52
Mirikizumab + PlaceboEli LillyPhase 2
52
LY4268989 + PlaceboEli LillyPhase 2
52
Eltrekibart + Mirikizumab + PlaceboEli LillyPhase 2
52

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85